4D Molecular Therapeutics (FDMT) 10-K 2023 FY Annual report

Exhibit 32.1

CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K (the “Annual Report”) of 4D Molecular Therapeutics, Inc. (the “Company”) for the year ended December 31, 2023, David Kirn, as Chief Executive Officer of the Company, and Uneek Mehra, as Chief Financial Officer of the Company, each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

a)

the Company’s Annual Report for the year ended December 31, 2023 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

b)

the information contained in such Annual Report fairly presents, in all material respects, the financial condition and results of operations of 4D Molecular Therapeutics, Inc.

Dated: February 29, 2024

By:	/s/ David Kirn
	David Kirn
	Chief Executive Officer
	(Principal Executive Officer)

Dated: February 29, 2024

By:	/s/ Uneek Mehra
	Uneek Mehra
	Chief Financial and Business Officer
	(Principal Financial and Accounting Officer)